Literature DB >> 10882580

Humoral immune responses in the hantavirus cardiopulmonary syndrome.

M Bharadwaj1, R Nofchissey, D Goade, F Koster, B Hjelle.   

Abstract

The immunologic responses that mediate viral clearance of and recovery from hantavirus cardiopulmonary syndrome (HCPS) due to Sin Nombre (SN) virus are unknown. Serial serum samples from 26 patients with acute SN virus infection were tested for IgG, IgA, and IgM reactivity to recombinant viral nucleocapsid (N) and glycoprotein G1 antigens by a novel strip immunoblot assay. The titers of antibodies capable of neutralizing SN virus in vitro also were determined for each sample. At admission, patients with severe disease had lower titers of IgG antibodies to SN virus N antigen (P<.033) and lower neutralizing antibody titers (P<3.4x10-5), compared with patients with mild disease. These data suggest that a strong neutralizing antibody response may be a predictor of effective clearance of and recovery from SN virus infection and raise the possibility that passive immunotherapy may be useful in HCPS.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10882580     DOI: 10.1086/315657

Source DB:  PubMed          Journal:  J Infect Dis        ISSN: 0022-1899            Impact factor:   5.226


  47 in total

Review 1.  The Syrian hamster model of hantavirus pulmonary syndrome.

Authors:  David Safronetz; Hideki Ebihara; Heinz Feldmann; Jay W Hooper
Journal:  Antiviral Res       Date:  2012-06-15       Impact factor: 5.970

2.  Confirmation of Choclo virus as the cause of hantavirus cardiopulmonary syndrome and high serum antibody prevalence in Panama.

Authors:  Randin Nelson; Raul Cañate; Juan Miguel Pascale; Jerry W Dragoo; Blas Armien; Anibal G Armien; Frederick Koster
Journal:  J Med Virol       Date:  2010-09       Impact factor: 2.327

3.  Truncated hantavirus nucleocapsid proteins for serotyping Sin Nombre, Andes, and Laguna Negra hantavirus infections in humans and rodents.

Authors:  Takaaki Koma; Kumiko Yoshimatsu; Noemi Pini; David Safronetz; Midori Taruishi; Silvana Levis; Rika Endo; Kenta Shimizu; Shumpei P Yasuda; Hideki Ebihara; Heinz Feldmann; Delia Enria; Jiro Arikawa
Journal:  J Clin Microbiol       Date:  2010-03-24       Impact factor: 5.948

Review 4.  Treatment of hantavirus pulmonary syndrome.

Authors:  Colleen B Jonsson; Jay Hooper; Gregory Mertz
Journal:  Antiviral Res       Date:  2007-11-21       Impact factor: 5.970

5.  Utilization of hantavirus antibody results generated over a five-year period to develop an improved serologic algorithm for detecting acute Sin Nombre hantavirus infection.

Authors:  Harry E Prince; Xin Su; Wayne R Hogrefe
Journal:  J Clin Lab Anal       Date:  2007       Impact factor: 2.352

6.  Highly differentiated, resting gn-specific memory CD8+ T cells persist years after infection by andes hantavirus.

Authors:  Tobias Manigold; Andrés Mori; Rebecca Graumann; Elena Llop; Valeska Simon; Marcela Ferrés; Francisca Valdivieso; Constanza Castillo; Brian Hjelle; Pablo Vial
Journal:  PLoS Pathog       Date:  2010-02-19       Impact factor: 6.823

7.  Elevated generation of reactive oxygen/nitrogen species in hantavirus cardiopulmonary syndrome.

Authors:  Ian C Davis; Allan J Zajac; Kurt B Nolte; Jason Botten; Brian Hjelle; Sadis Matalon
Journal:  J Virol       Date:  2002-08       Impact factor: 5.103

8.  Adenovirus vectors expressing hantavirus proteins protect hamsters against lethal challenge with andes virus.

Authors:  David Safronetz; Nagendra R Hegde; Hideki Ebihara; Michael Denton; Gary P Kobinger; Stephen St Jeor; Heinz Feldmann; David C Johnson
Journal:  J Virol       Date:  2009-04-29       Impact factor: 5.103

9.  The adaptive immune response does not influence hantavirus disease or persistence in the Syrian hamster.

Authors:  Joseph Prescott; David Safronetz; Elaine Haddock; Shelly Robertson; Dana Scott; Heinz Feldmann
Journal:  Immunology       Date:  2013-10       Impact factor: 7.397

10.  First human isolate of Hantavirus (Andes virus) in the Americas.

Authors:  Hector Galeno; Judith Mora; Eliecer Villagra; Jorge Fernandez; Jury Hernandez; Gregory J Mertz; Eugenio Ramirez
Journal:  Emerg Infect Dis       Date:  2002-07       Impact factor: 6.883

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.